AU Patent

AU2023379454A1 — Decreased retention of miniproteins in kidney

Assigned to Aktis Oncology Inc · Expires 2025-05-29 · 1y expired

What this patent protects

Provided herein are compositions and methods of treating, diagnosing, monitoring, and/or imaging a disease, disorder, or condition using radiopharmaceuticals selective for various targets. More specifically, compositions and methods disclosed herein decrease kidney retention or p…

USPTO Abstract

Provided herein are compositions and methods of treating, diagnosing, monitoring, and/or imaging a disease, disorder, or condition using radiopharmaceuticals selective for various targets. More specifically, compositions and methods disclosed herein decrease kidney retention or potential reuptake in the kidney where the targets are expressed in the kidney. Various approaches are disclosed to mitigate kidney retention of radiopharmaceuticals.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023379454A1
Jurisdiction
AU
Classification
—
Expires
2025-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Aktis Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.